What's Happening?
IDEAYA Biosciences announced plans to initiate a New Drug Application (NDA) submission for darovasertib in combination with crizotinib for first-line HLA*A2-negative metastatic uveal melanoma. This submission will be under the FDA's Oncology Center of
Excellence Real-Time Oncology Review (RTOR) program. The RTOR program allows for pre-submission of NDA components, enabling the FDA to review clinical trial data before the complete filing is submitted. IDEAYA's Phase 2/3 OptimUM-02 trial met its primary endpoint, showing a 58% reduction in disease progression risk and a significant improvement in median progression-free survival. The company plans to start the RTOR submission in May 2026, with the complete NDA filing expected in the second half of the year.
Why It's Important?
The RTOR program aims to expedite the review process, potentially bringing effective treatments to patients sooner. For IDEAYA, this represents a significant step in addressing the unmet needs of patients with metastatic uveal melanoma, a condition with limited treatment options. The positive trial results bolster the potential of darovasertib as a viable treatment, which could lead to improved patient outcomes and broaden IDEAYA's market presence in oncology. Successful approval could also enhance IDEAYA's reputation and financial standing, attracting further investment and partnerships.
What's Next?
IDEAYA will proceed with the RTOR submission process, targeting the first pre-submission in May 2026. The company will also present full trial results at the 2026 American Society of Clinical Oncology (ASCO) annual meeting. As the NDA process progresses, IDEAYA will likely engage with the FDA to address any queries and ensure a smooth review process. The outcome of this submission could influence IDEAYA's strategic decisions and future research directions.
